To understand why the study matters, it helps to understand what biosimilars are and how they differ from the generic drugs most consumers know. Conventional small-molecule medications can be copied exactly, and their generics must demonstrate bioequivalence through relatively straightforward testing. Biologic drugs, by contrast, are large, complex molecules manufactured inside living cells, which makes them inherently variable and impossible to replicate precisely. Biosimilars are therefore defined as products that are highly similar to an originator biologic, with no clinically meaningful differences in safety, purity or potency. A federal policy enacted in 2009 established an abbreviated regulatory pathway designed to bring these products to the U.S. market, with the explicit goals of increasing competition, lowering prices and improving access to biologic treatments. By the end of 2024, thirteen biosimilars had been approved for three of the most widely used cancer biologics: bevacizumab, rituximab and trastuzumab, drugs deployed against breast cancer, lymphoma, colorectal cancer, lung cancer and ovarian cancer.

The financial stakes in oncology could hardly be higher. Previous research has estimated that financial toxicity, the measurable hardship caused by the cost of care, may affect as many as half of all patients with cancer in the United States. That hardship is not merely a matter of household budgets; it has been linked to medication nonadherence and poorer health outcomes, meaning that high drug prices can directly undermine the effectiveness of treatment. Biologic drugs are a major contributor to this burden because of their complexity and cost. While earlier studies had shown that biosimilar competition in other therapeutic areas can drive down prices and shift prescribing toward cheaper alternatives, far less was known about what happened across these three major cancer drugs after biosimilar entry, and crucially, whether any market changes actually translated into lower costs for insurers and patients in everyday cancer care.

To close that gap, the UCLA team conducted a retrospective cohort study built on health insurance claims data. They identified 14,655 patient-drug pairs involving people with cancer who initiated treatment with bevacizumab, rituximab or trastuzumab between 2020 and 2023, a period that spans the market entry of biosimilars for all three drugs. The cohort included patients with commercial insurance as well as those with Medicare-related coverage, and the researchers tracked each patient’s treatment and costs for twelve months after the start of biologic therapy. Patients were sorted into four groups: those who exclusively used a biosimilar, those who exclusively used the originator product, those who switched from the originator to a biosimilar, and those who switched from a biosimilar back to the originator. Monthly insurer payments and patient out-of-pocket costs, calculated as the sum of deductibles, copayments and coinsurance, were compared across the groups after adjusting for differences in patient characteristics and treatment patterns.

The adoption patterns the researchers observed were striking. Among the patient-drug pairs, 59.4 percent of patients exclusively used a biosimilar during the first twelve months of treatment, while 32.5 percent exclusively used the originator. Only 6.9 percent switched from the originator to a biosimilar, and a mere 1.2 percent moved in the opposite direction. In other words, biosimilars captured the market primarily at the point of treatment initiation rather than through conversion of patients who were already mid-course on the branded drugs. That distinction carries practical weight: it suggests that the moment a clinician and patient choose which biologic to start may be the single most important leverage point for expanding the use of lower-cost alternatives, since switching established patients appears to be relatively rare.

The cost differences between the groups were substantial. After adjustment, average monthly payer costs were $8,959 for patients who exclusively used biosimilars, compared with $12,779 for those who exclusively used the originator, a gap of $3,820 every month of treatment. Out-of-pocket savings were smaller in absolute terms but still meaningful: patients on biosimilars paid an average of $118.90 per month versus $158.40 for those on originators, a difference of $39.50 per month. Senior author Tina Shih, director of the Cancer Health Economics Research Program at the UCLA Health Jonsson Comprehensive Cancer Center and professor of Health Economics in the Department of Radiation Oncology, acknowledged the asymmetry but emphasized its human significance. Although the savings were substantially greater for insurers than for patients, she noted, even modest reductions in out-of-pocket costs may be meaningful for people facing the financial challenges of cancer care, since those savings can be directed toward other treatment-related expenses or everyday living costs.

Beyond the patient-level comparisons, the study documented clear market-wide effects of biosimilar entry. The average sales price of the three originator biologics declined by 3.8 percent per year after biosimilars entered the market, evidence that competition pressured the branded products themselves rather than simply carving off a slice of demand. Meanwhile, the originators’ market share fell by roughly 30 percent annually among patients with commercial insurance and 31.5 percent within Medicare Part B. The biosimilars themselves were also becoming cheaper over time: the average sales price of the twelve biosimilar products included in the study declined by 12.4 percent per year, a pattern consistent with intensifying price competition among multiple manufacturers of similar products. Together, these trends indicate that the biosimilar pathway is functioning as intended, reshaping prices across the entire category rather than at the margins.

First author Xiaoyu Liu, a former PhD student in the Department of Health Policy and Management at the UCLA Fielding School of Public Health, framed the findings as timely support for ongoing regulatory efforts. The FDA has continued to take regulatory actions aimed at further unlocking biosimilar competition, Liu said, and the study’s results offer further evidence to support patients, providers and insurers in their consideration of biosimilars. The research team also included Xiaoyi Xu and Z. JohnLu of UCLA. Because the analysis relied on insurance claims rather than clinical records, it speaks primarily to utilization and cost rather than to treatment outcomes, but the regulatory standard for biosimilars, no clinically meaningful differences from the originator, underpins the assumption that the cheaper products deliver equivalent care. The study’s retrospective design also means the associations reflect real-world prescribing behavior rather than a controlled experiment, which is precisely what makes them valuable for policy discussions.

Taken together, the findings sketch a healthcare market in transition. Biosimilars now account for the majority of new treatment starts across three of oncology’s most important biologics, their prices are falling year over year, and their presence is pulling down the prices of the branded originals as well. For the health system, the monthly savings of nearly $4,000 per patient on payer costs represent the kind of aggregate figure that could reshape oncology budgets if adoption continues to climb. For individual patients, the roughly $40 in monthly out-of-pocket relief is modest against the backdrop of cancer’s total financial toll, yet it arrives at a time when financial toxicity affects up to half of American cancer patients and contributes to treatment abandonment and worse outcomes. The study also highlights a practical prescription: because biosimilar uptake happens overwhelmingly at treatment initiation, clinicians, insurers and policymakers who want to widen access to these equally efficacious, lower-cost alternatives should focus their efforts on the first prescription, where the choice between originator and biosimilar is actually made.

Subject of Research: Economic impact of biosimilar competition on cancer biologic drug costs for insurers and patients

Article Title: Cancer biosimilars associated with lower costs for insurers and patients, UCLA study finds

Article References: Cancer biosimilars associated with lower costs for insurers and patients, UCLA study finds. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: biosimilars, cancer biologics, bevacizumab, rituximab, trastuzumab, drug pricing, financial toxicity, JAMA Oncology, UCLA, health economics, Medicare Part B, FDA regulation

The findings arrive at a moment when the clinical rationale for prebiopsy imaging has never been stronger. Multiple randomized trials have demonstrated that imaging the prostate before obtaining tissue, and then using those images to target suspicious lesions, detects more of the clinically significant, aggressive cancers that genuinely threaten a patient’s life, while reducing the detection of indolent tumors that might otherwise trigger unnecessary treatment. This evidence base has prompted professional guidelines to progressively strengthen their endorsement of MRI as a standard step before needles are placed. What had remained unknown until now, however, was whether that accumulating evidence had actually changed what happens in hospitals and clinics across the country.

To answer that question, the research team, including lead clinical research biostatistician Stephen Rhodes of the UH Urology Institute, turned to Epic Cosmos, a large-scale database built from electronic health records spanning many health systems nationwide. Unlike earlier studies that relied on insurance claims data, which often lag behind real-world practice and miss patients whose care crosses different payers, the electronic health record approach captures what actually happened to individual patients at the point of care. The scale of the dataset, encompassing more than half a million biopsies over nearly a decade, allowed the researchers to track utilization trends with unusual granularity, including how patterns differed by whether a man was undergoing his first biopsy or a repeat procedure after a previously negative result.

The trajectory was striking in both groups, but for slightly different reasons. Among men with a prior negative biopsy, where the evidence supporting MRI was established earliest and where the procedure has long been recommended to help explain persistent elevations in prostate-specific antigen, MRI use rose from 38 percent in 2017 to 67 percent by the first half of 2026. Among biopsy-naive men, the increase was even more dramatic in relative terms, nearly a fivefold rise over the study period. Rhodes described the pace of change as genuinely rapid, noting that the timing tracks closely with the publication of the major randomized trials and their successive adoption into clinical guidelines. In an era when many evidence-based practices take fifteen to twenty years to diffuse into routine care, a near-complete transformation of biopsy practice within less than a decade represents an unusually swift example of evidence translation.

Yet the study’s authors are careful to emphasize that the story is one of substantial progress coexisting with persistent gaps. A full third of men undergoing a first prostate biopsy are still not receiving an MRI beforehand, which means the procedure is being performed, in effect, blind. That matters because the decision to image first changes two things simultaneously: whether a biopsy is needed at all, and, if it is, exactly where the needles should go. A man whose MRI shows no suspicious lesions may be spared the procedure entirely, avoiding the discomfort, bleeding risk, infection risk, and potential overdiagnosis that accompany blind sampling. A man whose scan reveals a concerning lesion can undergo targeted biopsies that are far more likely to find an aggressive cancer if one is present. Skipping the scan forfeits both benefits at once.

The senior author of the study, Jonathan Shoag, MD, Chief of the Division of Urologic Oncology and Director of the Prostate Cancer Program at University Hospitals, framed the problem in terms of quality measurement and equity. He noted that the true scope of the shortfall had been difficult to pin down before this analysis, with the best prior data, derived from insurance claims through 2022, suggesting MRI was used in only about 30 percent of biopsies. The motivation for the new study, he explained, was to establish a current, national picture: how many men are getting an MRI before biopsy today, and whether everyone is benefiting equally. Shoag said he still regularly sees patients who were biopsied at other institutions without a preceding MRI, and he attributes part of the persistent gap to access barriers and issues with insurance coverage, a well-recognized national problem that the new data now illuminate more clearly.

The analysis also surfaced patterns that the researchers found worth examining rather than simply accepting. MRI use fell off in two specific groups: men with very high PSA levels and men over the age of 80. In some cases, the authors suggest, this may reflect reasonable clinical judgment, since a markedly elevated PSA in an older patient may prompt an urgent diagnostic pathway in which imaging is perceived as a delay, and life expectancy considerations may alter the calculus for men in their ninth decade. But the researchers caution that these patterns deserve scrutiny rather than assumption. If otherwise appropriate candidates for imaging are being sent directly to biopsy out of habit, expedience, or lack of access, a measurable quality gap exists that health systems can and should audit. The study’s practical message for institutions is direct: track your own MRI rates by patient group, compare them against the evidence, and act on what the audit reveals.

Even where MRI is used, quality is not uniform, and the authors flag this as an ongoing concern for the field. Prostate MRI is a technically demanding examination that depends on scanner capability, protocol design, radiologist expertise, and structured reporting standards. A poor-quality scan can miss a clinically significant lesion, giving false reassurance, or overcall suspicious findings, triggering unnecessary biopsies. Shoag described how University Hospitals has invested in rigorously tracking MRI quality and performance and how it relates to biopsy outcomes, establishing workflows that give patients access to the latest imaging and biopsy techniques, including the transperineal approach, which carries a lower infection risk than the traditional transrectal route. He noted that the institution participated in the clinical trials that established these techniques as standards and has built a program to offer targeted biopsy with sedation to all patients, while also being an early adopter that made MRI accessible across its patient population.

Beyond the numbers, the study highlights how the diagnostic journey itself is being restructured around advanced imaging. Shoag described a coordinated model in which patients with elevated PSA levels are navigated through evaluation and decision-making, supported by a point-of-service scheduling initiative that books imaging and follow-up appointments before patients leave the office. The goal is to compress the interval between an abnormal screening result and a definitive answer, reducing the anxiety and drop-off that can occur when patients must coordinate multiple appointments across weeks. The institution is currently involved in multiple studies testing new tools to further improve prostate cancer diagnosis, suggesting that the rapid diffusion documented in this paper may be followed by another wave of refinements in how men are evaluated for the disease.

For patients, the study’s most actionable conclusion may be the simplest: any man facing a prostate biopsy should be asking whether an MRI beforehand is appropriate for him. For clinicians and health systems, the paper provides both a benchmark and a warning, documenting extraordinary progress in translating randomized trial evidence into practice while quantifying the gap that remains. With two thirds of men now imaged before their first biopsy and more than two thirds before repeat procedures, prebiopsy MRI has decisively entered the mainstream of American prostate cancer care. The remaining task, the authors suggest, is to close the residual gaps in access, coverage, and quality so that the benefits of targeted, image-guided diagnosis extend to every patient who stands to gain from them, rather than to a fortunate majority.

Subject of Research: National trends in prebiopsy MRI utilization for prostate cancer detection in the United States

Article Title: University Hospitals researchers find major increase in the use of MRI before prostate biopsy

Article References: University Hospitals researchers find major increase in the use of MRI before prostate biopsy. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prostate cancer, prebiopsy MRI, prostate biopsy, JAMA Oncology, University Hospitals, mpMRI imaging, targeted biopsy, transperineal biopsy, PSA screening, clinical guidelines, healthcare quality, Epic Cosmos

Cervical cancer is largely preventable through vaccination against human papillomavirus and detectable early through screening, yet it remains a major source of cancer deaths worldwide, particularly in low- and middle-income countries where screening programs are limited. For the subset of women whose disease recurs after treatment of the primary tumor or who present with metastatic disease at diagnosis, prognosis has historically been bleak. The mainstay of treatment for decades was combination chemotherapy, with or without the anti-angiogenic agent bevacizumab, which could slow the disease temporarily but rarely produced long-term control. Median survival in this setting had for years remained measured in months rather than years.

That landscape began to shift as researchers recognized that cervical cancer, despite being a virally driven malignancy, had characteristics that made it potentially susceptible to immune checkpoint blockade. Pembrolizumab, a monoclonal antibody that blocks the programmed cell death protein 1, or PD-1, receptor on T cells, releases a molecular brake that tumors use to disable the immune response. By preventing PD-1 from engaging its ligands, the drug allows cytotoxic T lymphocytes to recognize and attack tumor cells. The rationale for testing the drug in cervical cancer was reinforced by the observation of tumor-associated T-cell infiltration and the activity of pembrolizumab as a single agent in previously treated patients, which paved the way for a definitive test in the first-line, untreated setting.

KEYNOTE-826, the trial behind the new analysis, enrolled patients with persistent, recurrent, or metastatic cervical cancer who had not previously received systemic chemotherapy for their advanced disease. Participants were randomly assigned to receive their physician’s choice of standard chemotherapy, with or without bevacizumab, either alone or in combination with pembrolizumab. The trial used a double-blind, placebo-controlled design, meaning that neither patients nor the investigators assessing outcomes knew which treatment arm each patient had been assigned to, a rigor that strengthens the reliability of the comparisons. The study was stratified in ways that reflected known prognostic variables, including the use of bevacizumab, prior exposure to radiotherapy, tumor histology with separate accounting for squamous and adenocarcinoma subtypes, and PD-L1 expression status as determined by a validated combined positive score.

The initial reports of the trial demonstrated statistically significant and clinically meaningful improvements in the co-primary endpoints of overall survival and progression-free survival, along with higher response rates, among patients receiving pembrolizumab plus chemotherapy compared with chemotherapy alone. Those results led to regulatory approvals in the United States and elsewhere and changed practice guidelines internationally. Immunotherapy combinations, however, carry a distinctive uncertainty: unlike cytotoxic chemotherapy, whose effects are usually immediate and short-lived, immune-mediated responses can be durable but take time to fully manifest. The central question addressed by extended follow-up is whether the survival curves remain separated over many years, whether a meaningful fraction of patients remain progression-free long after treatment ends, and whether late toxic effects erode the benefit.

The five-year data reported in the new analysis provide reassurance on all three counts. The separation between treatment arms observed in earlier interim analyses persisted with longer follow-up, and the durability of benefit supports the interpretation that the early advantage was not an artifact of immature data. Patients with PD-L1-positive tumors, who represent the majority of those with advanced cervical cancer, derived particular benefit, consistent with the biological expectation that checkpoint blockade works best when the tumor microenvironment already harbors an immune response that has been suppressed rather than one that is absent altogether. The analysis also confirmed that the safety profile remained consistent with what had been established previously, without the emergence of concerning late-onset adverse events that would complicate the risk-benefit calculus.

For clinicians treating gynecologic cancers, the confirmation matters because it removes lingering doubt about whether to incorporate pembrolizumab into first-line treatment. When overall survival benefits are demonstrated at interim analyses with limited follow-up, some physicians defer adoption pending proof of durability, particularly when the regimen adds cost, requires regular infusions, and carries the risk of immune-related adverse events affecting organs such as the thyroid, lungs, colon, and kidneys. Five-year data showing that patients who received the combination were still alive and, in some cases, still without disease progression years after randomization provide the kind of evidence that persuades even cautious practitioners and health systems to make the regimen standard of care.

The findings also carry implications for how the field moves forward. With an immunotherapy-chemotherapy backbone now established as the foundation of first-line treatment for recurrent and metastatic cervical cancer, research attention is turning to questions the original trial was not designed to answer. These include whether biomarkers beyond PD-L1 expression can identify which patients stand to benefit most, whether the addition of bevacizumab is necessary for all patients or can be reserved for selected groups, whether novel agents such as antibody-drug conjugates can be layered onto the regimen safely, and whether patients who achieve long-term disease control can safely discontinue treatment. Trials exploring tissue-agnostic and site-specific combinations are already underway, building on the platform that KEYNOTE-826 validated.

There are limits to what even long-term randomized data can resolve. The exploratory nature of this analysis means that some subgroup findings should be interpreted with caution, as smaller patient numbers reduce statistical power and increase the chance that observed differences reflect chance rather than biology. Access remains a critical concern: pembrolizumab is expensive, and the populations with the highest burdens of cervical cancer often live in health systems where the drug is least available. Translating a five-year survival benefit demonstrated in an international trial into widespread clinical reality requires attention to drug pricing, health infrastructure, and the upstream interventions of HPV vaccination and screening that prevent advanced disease in the first place.

Nevertheless, the five-year results represent a milestone for a disease that, until recently, offered patients with recurrence little hope of extended survival. The demonstration that benefit endures converts an important interim finding into a settled standard and provides a reference point against which all future therapies for advanced cervical cancer will be measured. For the women treated on the trial, the data translate into years of life that would likely have been lost under the previous standard, and for the broader oncology community, they reinforce a principle that has gradually reshaped cancer medicine: when the immune system can be durably unleashed against a tumor, the benefits can outlast the treatment itself. The corresponding author of the analysis is Kosei Hasegawa, MD, PhD, of the Department of Gynecologic Oncology at Saitama Medical University International Medical Center in Japan, and the findings were published in JAMA Oncology under DOI 10.1001/jamaoncol.2026.3547.

Subject of Research: Pembrolizumab combined with chemotherapy as first-line treatment for recurrent and metastatic cervical cancer

Article Title: Pembrolizumab plus chemotherapy for cervical cancer

Article References: Pembrolizumab plus chemotherapy for cervical cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cervical cancer, pembrolizumab, KEYNOTE-826, immunotherapy, PD-1 inhibitor, chemotherapy, bevacizumab, JAMA Oncology, metastatic cancer, clinical trial, overall survival, gynecologic oncology